Labetalol and Glyceril trinitrate

PreclinicalSmall molecule

Labetalol and Glyceril trinitrate is one of 7 small molecule programs targeting Severe Pre-Eclampsia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Pre-EclampsiaActive, not recruiting

Severe Pre-EclampsiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Severe Pre-Eclampsia

#DrugCompanyPhaseTrials

Crestor

AstraZeneca

Approved

—2

Epsom Salt

FFresenius Kabi Oncology Ltd.

Approved

1 3

Normodyne

Lanoxin

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—6

Magnesium Sulfate Administration

UUniversity of California, San Francisco

Preclinical

1 7

Labetalol and Glyceril trinitrate

AAin Shams University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Severe Pre-Eclampsia1 trial

Nitroglycerin Versus Labetalol in Acute Severe Pre-eclampsia

Completed·—·N/A·NCT05310929·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Labetalol and Glyceril trinitrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Labetalol and Glyceril trinitrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Labetalol and Glyceril trinitrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ain Shams University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AAin Shams University

Labetalol and Glyceril trinitrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Severe Pre-Eclampsia1 trial

References

Drug Info

Quick Facts

Related News